Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes

Abstract

Purpose

We compared the individual effects of mitiglinide and glibenclamide administered in combination with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin on plasma DPP-IV activity and blood glucose levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes (STZ-NA rats).

Methods

We examined the inhibitory activity of mitiglinide and glibenclamide as well as their combination with sitagliptin on plasma DPP-IV activity in STZ-NA rats. The oral glucose tolerance test (OGTT) was used to compare effects of mitiglinide, glibenclamide, and their combination with sitagliptin on blood glucose levels in STZ-NA rats.

Results

Mitiglinide and glibenclamide did not inhibit rat DPP-IV and did not influence the inhibitory effect of sitagliptin on rat plasma DPP-IV activity. In STZ-NA rats, plasma glucose levels were stronger suppressed by a combination of mitiglinide and sitagliptin than by either drug used alone. However, no clear effect of the combination of glibenclamide and sitagliptin was observed.

Conclusion

These results indicate that the combination of mitiglinide and sitagliptin has a lower risk of hypoglycemia in the rats with induced type 2 diabetes compared with the combination of glibenclamide and sitagliptin. The combination of mitiglinide and sitagliptin can be a promising combination for the treatment of diabetic patients.

Key words

antidiabetic drugs - metabolic disorders - pharmacology

• References

• 1 IDF Diabetes Atlas. 2015; www.diabetesatlas.org
• 2 Japan Diabetes Society. Treatment Guide for Diabetes 2012–2013
• 3 Kim YG, Hahn S, Oh TJ. et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708
• 4 Yamaguchi S, Ikejima M, Furukawa A. et al. Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor. Diabetes Res Clin Pract 2015; 109: e8-e10
• 5 Ishii H, Ohkubo Y, Takei M. et al. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes. J Clin Med Res 2014; 6: 127-132
• 6 Umayahara R, Yonemoto T, Kyou C. et al. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocr J 2014; 61: 1163-1170
• 7 Shimoda S, Iwashita S, Sekigami T. et al. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. J Diabetes Investig 2014; 5: 320-326
• 8 Konya H, Katsuno T, Tsunoda T. et al. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013; 6: 317-325
• 9 Jung JA, Kaku K, Kim JH. et al. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Adv Ther 2013; 30: 1018-1029
• 10 Kaku K, Inagaki N, Kobayashi N. Long-term effects of mitiglinide in Japanese diabetics inadequately controlled with DPP-4 inhibitor or biguanide monotherapy. Diabetes Ther 2014; 5: 97-111
• 11 Kimura T, Shiosakai K, Takeda Y. et al. Quantitative evaluation of compliance with recommendation for sulfonylurea dose co-administered with DPP-4 inhibitors in Japan. Pharmaceutics 2012; 4: 479-493
• 12 Gangji AS, Cukierman T, Gerstein HC. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394
• 13 Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metabol Res Rev 2001; 17: 467-473
• 14 Ohnota H, Kitamura T, Kinukawa M. et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn J Pharmacol 1996; 71: 315-323
• 15 Ohnota H, Koizumi T, Tsutsumi N. et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994; 269: 489-495
• 16 Akahane K, Inoue T, Yokoyama A. et al. Efficacy of mitiglinide combined with dapagliflozin in streptozotocin-nicotinamide-induced type 2 diabetic rats and in zucker fatty rats. Drug Res 2015; 65: 416-421
• 17 Masiello P, Broca C, Gross R. et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47: 224-229
• 18 Fukushima H, Hiratate A, Takahashi M. et al. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem 2008; 16: 4093-4106
• 19 Yang J, Ba T, Chen L. et al. Effects of metformin and sitagliptin on glycolipid metabolism in type 2 diabetic rats on different diets. Arch Med Sci. 2016; 12: 233-242
• 20 Ahrén B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 2016; 59: 907-917
• 21 Kim D, Wang L, Beconi M. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-151
• 22 Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670
• 23 Herman GA, Bergman A, Liu F. et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876-886
• 24 Liu D, Ma X, Liu Y. et al. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. Eur J Pharm Sci 2016; 89: 73-82
• 25 Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 867-876
• 26 Ahrén B, Landin-Olsson M, Jansson PA. et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
• 27 Li L, Yang M, Li Z. et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnosed patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes Metab 2012; 14: 187-189
• 28 Salvo F, Moore N, Arnaud M. et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ 2016; 353: i2231
• 29 Mukai E, Fujimoto S, Inagaki N. Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas. Nihon Rinsho 2011; 69: 907 911
• 30 de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443